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Abstract The development of direct-acting antiviral
(DAA) agents has reinvigorated the treatment of hepatitis
C virus infection. The availability of multiple DAA agents
and drug combinations has enabled the transition to inter-
feron-free therapy that is applicable to a broad range of
patients. However, these DAA combinations are not
without drug–drug interactions (DDIs). As every possible
DDI permutation cannot be evaluated in a clinical study,
guidance is needed for healthcare providers to avoid or
minimize drug interaction risk. In this review, we evaluated
the DDI potential of the novel three-DAA combination of
ombitasvir, paritaprevir, ritonavir, and dasabuvir (the 3D
regimen) with more than 200 drugs representing 19 ther-
apeutic drug classes. Outcomes of these DDI studies were
compared with the metabolism and elimination routes of
prospective concomitant medications to develop mecha-
nism-based and drug-specific guidance on interaction
potential. This analysis revealed that the 3D regimen is
compatible with many of the drugs that are commonly
prescribed to patients with hepatitis C virus infection.
Where interaction is possible, risk can be mitigated by
paying careful attention to concomitant medications,
adjusting drug dosage as needed, and monitoring patient
response and/or clinical parameters.
Key Points
The three direct-acting antiviral combination of
ombitasvir, paritaprevir, ritonavir, and dasabuvir (3D
regimen) is a combination therapy that was recently
approved for the treatment of genotype-1 chronic
hepatitis C virus infection.
Potential drug–drug interactions with the 3D
regimen were identified by applying
pharmacokinetic study data to known routes of
metabolism and disposition of more than 200
prescription and over-the-counter drugs.
The majority of concomitant medications assessed
are compatible with 3D therapy. Where interaction is
possible, guidance on dose adjustment and/or clinical
monitoring are provided.
1 Introduction
The development of direct-acting antiviral agents (DAAs)
has revolutionized the treatment of chronic hepatitis C
virus (HCV) infection. In head-to-head comparisons,
combination therapy with DAAs has proven to be more
effective and better tolerated than interferon-based thera-
pies in both treatment-naı¨ve and treatment-experienced
patients [1–4]. One such investigational combination
includes ombitasvir, paritaprevir (identified as a lead
compound by AbbVie, Inc., North Chicago, IL, USA, and
Enanta Pharmaceuticals, Inc., Watertown, MA, USA),
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ritonavir, and dasabuvir, together known as the 3D regi-
men. Ombitasvir, paritaprevir, and dasabuvir combine
unique antiviral mechanisms of action (nonstructural pro-
tein 5A inhibition, nonstructural protein 3/4A protease
inhibition, and non-nucleoside nonstructural protein 5B
polymerase inhibition, respectively). This potent three-
class combination approach has achieved high rates of
sustained virologic response in a broad range of patients,
including those with cirrhosis or those who have undergone
liver transplant [5, 6]. The antiviral activity of paritaprevir
is boosted by its co-formulation with a low dose of riton-
avir (i.e., 100 mg), facilitating the use of a lower dose of
paritaprevir and once-daily dosing. Ritonavir is a strong
inhibitor of cytochrome P450 (CYP) 3A4, a major enzyme
involved in the metabolism of paritaprevir [7].
In pivotal clinical trials, the 3D regimen with ribavirin
achieved sustained virologic response rates at 12 weeks
(SVR12) of 94–100 % in treatment-naı¨ve and treatment-
experienced non-cirrhotic patients with genotype-1 HCV
and 93–100 % after 24 weeks of treatment in patients with
genotype-1 HCV and cirrhosis, including prior null respon-
ders [5, 8–11]. Additionally, in liver transplant recipients
with recurrent HCV genotype-1 infection and no cirrhosis
(Metavir BF2) at least 12 months after transplantation, 33 of
34 patients (97 %; 95 % confidence interval [CI] 85–100 %)
who were treated with the 3D regimen plus ribavirin for
24 weeks achieved SVR12 [6]. No graft rejection events
occurred during the study. The 3D regimen was well toler-
ated when administered with or without ribavirin; treatment
discontinuation rates were low and adverse events (AEs)
were generally mild [5, 6, 8–12]. In subjects receiving 3D
with ribavirin, the most commonly reported AEs (occurring
in[10 % of subjects) were fatigue, nausea, pruritus, other
skin reactions, insomnia, and asthenia. In subjects receiving
3D regimen without ribavirin, the most commonly reported
AEs (occurring in C5 % of subjects) were nausea, pruritus,
and insomnia. The safety profile of the 3D regimen was
similar in patients with cirrhosis [5] or who were post-
transplant [6] to that of the overall population and no sig-
nificant associations were found between ombitasvir,
dasabuvir, and ritonavir exposures and AEs or laboratory
abnormalities [13]. Exposure-safety analyses showed that
increases in paritaprevir exposure of up to 2-fold are not
predicted to meaningfully increase AEs or laboratory
abnormalities of Grade 3 or greater [13].
Comparisons of 3D pharmacokinetics in subjects with
hepatic impairment vs normal hepatic function demon-
strated that DAA exposures were not significantly affected
(\35 % change) in subjects with mild hepatic impairment
(Child-Pugh A) and, hence, no dosage adjustment of 3D
therapy is required for such patients [12]. In patients with
moderate hepatic impairment (Child-Pugh B), ombitasvir,
ritonavir, and dasabuvir area under the plasma
concentration-time curves (AUCs) decreased by 30 % or
less, whereas paritaprevir AUC increased by 62 % [12].
Because of these exposure changes, 3D therapy is not
recommended in patients with moderate hepatic impair-
ment. A more substantial effect on DAA exposures (54 %
decrease in ombitasvir and 325 and 945 % increase in
dasabuvir and paritaprevir, respectively) was observed in
patients with severe hepatic impairment (Child-Pugh C)
[12]. Therefore, 3D therapy is contraindicated in patients
with severe hepatic impairment.
Pharmacokinetic study data indicate that the presence of
mild, moderate, or severe renal impairment does not increase
DAA exposures to a clinically significant degree (\50 %
change); therefore, no dose adjustment is indicated for 3D
therapy when given to patients with renal impairment [14].
Food has been shown to significantly increase exposures
for 3D components, by as much as 82, 211, 49, and 30 %
for ombitasvir, paritaprevir, ritonavir, and dasabuvir,
respectively [12]. Fat and/or calorie content do not appear
to influence the magnitude of interaction. In all phase I–III
studies, 3D regimen components were administered with
food. Given the magnitude of the effect of food, 3D therapy
should be administered with food to maximize absorption.
As new therapeutic options for treating HCV become
available, it will be important to assess their abilities to
interact with established medications, particularly those
drugs or drug classes that are commonplace among patients
with HCV infection. Adverse drug reactions resulting from
concomitantly administered medications are an ongoing
concern for patients undergoing HCV treatment because of
the heavy burden of polypharmacy that coincides with a high
prevalence of comorbidities in this patient population [15–
17]. The interplay of therapies influences not only the safety
profile (via the potential for increasing drug exposures) but
also may reduce therapeutic efficacy in cases where meta-
bolic enzyme induction decreases circulating drug concen-
trations. Mechanistic data have shown a propensity for all
DAAs to act as substrates, inhibitors and/or inducers of
metabolic enzymes, and transporters, which is the founda-
tion for the observed drug–drug interactions (DDIs) [18, 19].
In clinical practice, non-HCV medications that have the
potential for interactions with HCV treatments are fre-
quently prescribed to patients with chronic HCV infection
[20, 21]. In a recent study, more than half of the medica-
tions that were commonly prescribed to a large represen-
tative sample of patients with chronic HCV infection
(N = 53,461) were found to have interaction potential with
telapravir and boceprevir.[21] However, later-generation
DAAs represent an improvement in DDI propensity com-
pared with the first-generation protease inhibitors.
Pharmacokinetic studies are the ideal method by which
to evaluate the DDI potential of the 3D regimen; however,
such an undertaking is not feasible given the number of
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prescription and over-the-counter medications available
and their various permutations. In recognition of these
limitations, regulatory agencies have created recommen-
dations regarding which drugs should be studied to inter-
rogate potential enzymatic and transporter pathways that
may lead to significant DDIs [22, 23]. With results from
key DDI studies, data can then be extrapolated to other
medications based on what is known about drug
metabolism.
To provide clear guidance regarding the clinical use of
the 3D regimen and facilitate prescription decisions, in this
report, we have gathered information on the metabolism
and disposition of more than 200 commonly used drugs.
These data, together with DDI studies involving the 3D
regimen, were used to develop recommendations for DDI
evaluation and management. In addition, these recom-
mendations were successfully implemented for co-medi-
cation management in the pivotal phase III clinical trials of
the 3D regimen and are also being implemented in the
ongoing phase IIIb studies.
2 Metabolic Characteristics of 3D Regimen
Components
In vitro preclinical and human pharmacokinetic studies
have demonstrated that several enzymes and transporters
are involved in the disposition of 3D regimen components.
All DAAs show minimal renal elimination. The presence
of ombitasvir, paritaprevir, and dasabuvir in feces suggests
possible involvement of biliary excretion for these drugs.
Within the family of CYP isoenzymes, paritaprevir and
ritonavir are chiefly metabolized by CYP3A, whereas
dasabuvir metabolism occurs primarily through CYP2C8
with minor contribution by CYP3A [12, 24, 25]. Ombi-
tasvir is mainly metabolized by amide hydrolysis. The
DAAs are not expected to inhibit/induce CYP enzymes,
although ritonavir is a known strong inhibitor of CYP3A
[12], and the 3D regimen has been shown to modestly
induce CYP1A2 and CYP2C19 in vivo [25, 26], which is
attributed to the effects of ritonavir.
In general, marketed and in-pipeline DAAs attain suf-
ficient hepatocellular concentrations to inhibit HCV repli-
cation because they are substrates of hepatic transporters.
This property also explains why these HCV therapeutic
agents may interact with multiple drugs.
Components of the 3D regimen act as both substrates
and inhibitors of transport proteins. The results of in vitro
studies indicate involvement of one or more 3D agents as
substrates and/or inhibitors of p-glycoprotein (P-gp), breast
cancer resistance protein (BCRP), and organic anion
transporting polypeptides 1B1 and 1B3 (OATP1B1/B3)
(Table 1). However, none of the 3D components are sub-
strates or inhibitors of renal transport proteins, including
organic anion transporters (OAT1, OAT3), organic cation
transporters (OCT1, OCT2), or multi-drug and toxin
extrusion proteins (MATE1 and MATE2K), at clinically
relevant concentrations [12, 24, 25].
Ombitasvir, paritaprevir, and dasabuvir inhibit uridine
diphosphate glucuronosyltransferase (UGT) 1A1 [12, 24,
25]; however, the 3D regimen is not expected to inhibit
UGT1A4, UGT1A6, UGT1A9, and UGT2B7 at clinically
relevant concentrations. Historically, in vivo data have
shown that ritonavir causes UGT1A1 induction [27, 28];
however, based on drug interaction data with raltegravir (a
UGT1A1 substrate), the net effect of the 3D regimen is
UGT1A1 inhibition (Fig. 1) [29].
2.1 DDI Studies with the 3D Regimen
Eighteen formal interaction studies in healthy volunteers
have been performed to evaluate the DDI potential of the
3D regimen with selected drugs, also known as probes,
based on their disposition via a metabolic enzyme and/or
transporter pathway [25]. In these scenarios, the 3D regi-
men functioned either as (i) the ‘victim’, wherein the
pharmacokinetics of one or more 3D agents were influenced
by the presence of another drug, or (ii) the ‘perpetrator’, in
which the 3D regimen affected the pharmacokinetics of the
probe. Selection of probes was derived from general
industry guidance issued by the US Food and Drug
Administration and European Medicines Agency [22, 23].
Table 1 3D regimen
components as substrates or
inhibitors of transport proteinsa
Transporter Substrate Inhibitor
Ombitasvir P-gp
Paritaprevir P-gp, BCRP, OATP1B1/B3 P-gp, BCRP, OATP1B1/B3
Dasabuvir P-gp, BCRP P-gp, BCRP
Ritonavir P-gp P-gp, BCRP
BCRP breast cancer resistance protein, OATP1B1 organic anion transporting polypeptide 1B1, OATP1B3
organic anion transporting polypeptide 1B3, P-gp p-glycoprotein, 3D direct-acting antiviral agent com-
bination of ombitasvir, paritaprevir, ritonavir, and dasabuvir
a Findings are based on in vitro data [24]
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Results from these mechanistic studies form the foundation
for recommendations in this paper on dose adjustments for a
wide range of drugs in various classes based on similar
pharmacokinetic pathways. A summary of the results of
these evaluations is presented in Fig. 1.
3 DDI Potential of Concomitantly Administered
Medications by Therapeutic Class
Using the results of the mechanistic studies described
above, the potential for interactions of the 3D regimen with
other commonly administered medications were deter-
mined based on the agents’ pharmacokinetic profiles.
Route of elimination information and other relevant influ-
ences on metabolism were identified from the published
literature and/or prescribing information for more than 200
drugs. The following section describes the results of this
analysis parsed by drug class. The ensuing dosing recom-
mendations are summarized in Table 2.
With the vast size of the pharmaceutical armamentar-
ium, a review of all of the possible drug interactions within
the confines of this report is not possible. Therefore, in an
effort to simplify the identification and management of
drugs that may influence or be influenced by the 3D regi-
men, we have created the algorithm for screening and dose
adjustment shown in Fig. 2.
3.1 Analgesics/Anti-inflammatory Agents
Within the analgesic/anti-inflammatory class, distinctions
can generally be made between the interactions of
nonsteroidal anti-inflammatory drugs (NSAIDs)/COX-2-
selective inhibitors and opioids. Metabolism of many of the
NSAIDs/COX-2 inhibitors predominantly involves
CYP2C9 and/or members of the UGT family [30–42]. The
lack of interaction between the model CYP2C9 substrate,
warfarin, and the 3D regimen indicates that no dose
adjustment would be required for drugs predominantly
metabolized via CYP2C9 (Fig. 1) [25]. Moreover, the only
interaction potential for a UGT species was that of
UGT1A1, as demonstrated by the DDI study with ralte-
gravir as the model substrate [24]. The involvement of
multiple UGTs in NSAID glucuronidation likely minimizes
Fig. 1 Formal interaction studies performed with the direct-acting
antiviral agent combination of ombitasvir, paritaprevir, ritonavir, and
dasabuvir (3D regimen) and their implications on dose recommen-
dations for other drugs. A change in exposure (maximum concentra-
tion [Cmax] or area under the plasma concentration-time curve [AUC])
of B20 % is considered to be not clinically significant. a No
significant change was observed in exposures for norcyclobenzaprine,
the major metabolite of cyclobenzaprine. BCRP breast cancer
resistance protein, CYP cytochrome P450, OAT organic anion
transporter, OATP organic anion transporting polypeptide, P-gp p-
glycoprotein, UGT uridine 50-diphospho-glucuronosyltransferase.
Data sources: [25, 26, 29, 69]
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Table 2 Drug–drug interaction (DDI) potential of commonly administered medications
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Table 2 continued
Class (use in pivotal trials)a No expected DDI Require possible dose
adjustment
Contra-indicated











Saxagliptin (limit dose to
2.5 mg once daily)
None
a1-Adrenergic blockers (26 % of patients)
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Table 2 continued
Class (use in pivotal trials)a No expected DDI Require possible dose
adjustment
Contra-indicated
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any effect that the 3D regimen may have on UGT1A1-
based catalysis by providing alternate routes of metabolism
[37]. Notable exceptions to the general metabolism/elimi-
nation pattern for NSAIDs include acetaminophen, for
which a 3D DDI study demonstrated minimal pharma-
cokinetic interaction (\20 % change in exposure) during
concomitant therapy [26]; aspirin, which undergoes
deacetylation and subsequent glucuronidation [43];
ketorolac, which has a large renal excretion component
[44]; and meloxicam, for which CYP3A4 plays a role [45].
The 3D regimen-mediated inhibition of CYP3A4 may
increase meloxicam exposure; therefore, a dose reduction
for meloxicam should be considered when it is co-admin-
istered with the 3D regimen. Table 2 provides a list of
analgesics and anti-inflammatory agents that can be used
with the 3D regimen without any dose adjustment.
Contribution of CYP3A4 to the metabolism of most
opioids (e.g., fentanyl, hydrocodone, hydromorphone,
meperidine/pethidine, oxycodone, and tramadol) [46–54]
indicates the potential for an interaction with the 3D reg-
imen that would lead to increased drug exposure of the
opioids. Hydrocodone AUC increased by 90 % when given
with the 3D regimen in a DDI study [26]. A 50 % reduction
in hydrocodone dose is, therefore, recommended when
administered with the 3D regimen. The other listed opioids
should be used with caution and dose reduction is recom-
mended when given concomitantly with the 3D regimen.
Buprenorphine, another opioid, is a CYP3A substrate but
no dose adjustment is recommended based on a modest
interaction with the 3D regimen and the lack of effect on
pharmacodynamic parameters [25]. In a DDI study with the
3D regimen, no interaction was observed with naloxone
[25]; consequently, no dose adjustment is needed during
co-administration. Codeine, morphine, and methadone are
unlikely to require dose adjustment when given with 3D
therapy because CYP3A4 is not the only or the primary
Table 2 continued
Class (use in pivotal trials)a No expected DDI Require possible dose
adjustment
Contra-indicated



















Thyroid replacement therapy (7 % of patients) None Levothyroxined None
OCPs oral contraceptive pills, PAH pulmonary arterial hypertension, 3D direct-acting antiviral agent combination of ombitasvir, paritaprevir,
ritonavir, and dasabuvir
: dose increase recommended, ; dose decrease recommended
a Percentage of patients who received the class of drugs concomitantly for at least 6 weeks during treatment with the 3D regimen in pivotal
clinical trials [227]
b For these drugs, formal DDI studies have been performed with the 3D regimen [25, 26]
c The percentage represents patients who received antihypertensive agents, antiarrhythmic agents, antiplatelet agents/anticoagulants, diuretics or
a1-adrenergic blockers for at least 6 weeks during treatment with 3D regimen in pivotal clinical trials [227]
d Suggest monitoring drug levels or clinical response or side effects during 3D treatment to determine dose adjustment requirements
e No dose adjustment needed for individuals with normal renal function
f Budesonide, fluticasone, and voriconazole should only be used with the 3D regimen if the potential benefits outweigh the risks of treatment
g Limit dose to 25 mg every 48 h for the treatment of erectile dysfunction
h Limit dose to 10 mg every 72 h for erectile dysfunction; initiate 20 mg once daily for PAH after at least 1 week of 3D treatment. The dose may
be increased to 40 mg once daily if tolerated and clinically indicated
i Limit dose to 2.5 mg every 72 h for erectile dysfunction; initiate 20 mg once daily for PAH after at least 1 week of 3D treatment. The dose
may be increased to 40 mg once daily if tolerated and clinically indicated
j Administer 4 h after 3D administration
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metabolic enzyme for these drugs [55–57]. Indeed, a DDI
study with methadone and the 3D regimen revealed no
increase in methadone exposure with concomitant admin-
istration (Fig. 1) [25].
3.2 Antidepressants
Drug–drug interactions with the 3D regimen are not
expected for most antidepressants. The 3D regimen showed
no significant interaction with the antidepressants dulox-
etine (a CYP2D6/CYP1A2 substrate) or escitalopram (a
CYP2C19/CYP3A4 substrate) in DDI studies (Fig. 1) [25].
Although the 3D regimen would be anticipated to decrease
escitalopram exposure through CYP2C19 induction, the
effects are likely offset by CYP3A4 inhibition. These
results can be extrapolated to citalopram, which is a race-
mic mixture of escitalopram and (R)-citalopram. In addi-
tion, the 100-mg dose of ritonavir that is part of the 3D
regimen is not expected to interact with substrates of
CYP2D6 based on data with ritonavir 200 mg and the HIV
protease inhibitor lopinavir [58]. Thus, fluoxetine and
paroxetine are unlikely to exhibit pharmacokinetic inter-
actions with the 3D regimen, as they are also substrates of
CYP2D6 [59, 60]. No DDIs are expected for milnacipran
because it is primarily excreted renally and shows minimal
CYP450-related metabolism [61]. Standard dosing for
these antidepressants are warranted when given with the
3D regimen.
Historically, in vivo studies suggest an interaction
between bupropion (CYP2B6 substrate) and ritonavir, with
long-term administration of ritonavir 200 mg daily reduc-
ing bupropion exposure by as much as 22 % [62]. How-
ever, no clinically significant interaction between the 3D
regimen and bupropion, a CYP2B6 substrate, is expected
based on studies of methadone, another CYP2B6 substrate,
and the low dose (100 mg) of ritonavir that is co-formu-
lated with the 3D regimen. Hence, initial dose modification
is not needed for bupropion when administered with the 3D
regimen. Clinical monitoring is recommended, with dose
adjustment based on clinical symptoms.
The metabolism of fluvoxamine has not been fully
elucidated, but is believed to be predominantly mediated
by CYP1A2, with minor involvement of CYP3A4 and
CYP2C19 [63]. Fluvoxamine also functions as a moderate
inhibitor of CYP3A4 and CYP2C19. As a potential sub-
strate or inhibitor of CYPs, alterations in pharmacokinetics
are possible with co-administration of fluvoxamine and the
3D regimen. Caution should be exercised in prescribing
fluvoxamine for patients receiving 3D therapy, and dose
adjustment of fluvoxamine may be considered, depending
on the clinical response.
Dose reduction is recommended for mirtazapine [64],
reboxetine [65], sertraline [66], trazodone [67], and ven-
lafaxine [68] when administered with the 3D regimen
because of the potential for an increase in drug exposure
resulting from the inhibitory effects of the 3D regimen on
CYP3A4.
Because of the potential for decreased ombitasvir, par-
itaprevir, ritonavir, and dasabuvir exposures and com-
mensurate loss of therapeutic efficacy, the herbal
antidepressant St. John’s Wort is contraindicated for use
with the 3D regimen [12].
3.3 Antacids/Proton Pump Inhibitors
The influence of acid reduction on 3D regimen pharma-
cokinetics was evaluated in a DDI study with omeprazole.
The maximum concentration (Cmax) and AUC values for
ombitasvir, paritaprevir, ritonavir, and dasabuvir were only
minimally effected (\20 % change in exposure); however,
a 38 % reduction in omeprazole exposure was observed
(Fig. 1) [25, 69]. The results of this study indicate that
(i) acid reduction, per se, does not significantly alter the
pharmacokinetics of the 3D regimen, and (ii) a dose
increase should be considered for substrates of CYP2C19,
if a decrease in clinical response is noted. Other proton
pump inhibitors (listed in Table 2), follow a similar
metabolic pathway [70–74] and dose increases are rec-
ommended if clinically indicated. However, dose
Fig. 2 Proposed algorithm for screening, dose adjustment, and
monitoring of potential drug interactions with the direct-acting
antiviral agent combination of ombitasvir, paritaprevir, ritonavir,
and dasabuvir (3D regimen). CYP cytochrome P450, OAT organic
anion transporter, OATP organic anion transporting polypeptide, P-gp
p-glycoprotein, UGT uridine 50-diphospho-glucuronosyltransferase
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adjustment is not expected for histamine H2-receptor
antagonists (cimetidine, famotidine, ranitidine), which
primarily undergo renal elimination [75–77]. In addition,
in vitro chelation experiments with the 3D regimen indicate
that calcium, magnesium, and aluminum-based antacids
will not interact with the 3D regimen.
3.4 Diuretics
Dose adjustment is not warranted for the majority of
diuretics when given with the 3D regimen. Amiloride,
chlorthalidone, and hydrochlorothiazide undergo minimal
hepatic metabolism and, hence, are not expected to
demonstrate a metabolic interaction with the 3D regimen
[78–80]. Triamterene primarily undergoes sulfonation and
there is no evidence of overlapping metabolic or trans-
porter pathways with that of the 3D regimen [81]. The
metabolism of torsemide predominantly involves CYP2C9,
with a minor contribution from CYP2C8 [82, 83]. As
demonstrated by the warfarin/3D DDI study, the CYP2C9
substrate does not show significant interaction with the 3D
regimen (Fig. 1) [25].
Dose adjustment may be necessary for furosemide and
xipamide. In a DDI study, concomitant administration of
furosemide and the 3D regimen increased the Cmax of
furosemide by 42 %, although minimal change (8 %) in
AUC was observed [25]. The exact mechanistic reason for
the greater increase in furosemide Cmax vs AUC is
unknown but UGTs, including UGT1A1, may be a con-
tributing factor. Clinical monitoring of patients receiving
furosemide is recommended, with a possible dose reduc-
tion by as much as 50 %. Because the involvement of
UGT1A1 cannot be ruled out, clinical monitoring is also
suggested for patients who receive concomitant xipamide,
with dose adjustment if clinically indicated.
3.5 Antiplatelet Agents/Anticoagulants
Antiplatelet agents and anticoagulants are highly diverse in
disposition, although none of the pathways are anticipated
to lead to clinically relevant DDIs with the 3D regimen.
Mechanisms including deacetylation and glucuronidation
by various UGT species (aspirin) [43], desulfation and/or
depolymerization (enoxaparin) [84], renal excretion (fon-
daparinux) [85], and CYP2C9/CYP1A2 metabolism
(acenocoumerol, fluindione, warfarin) [86–88] are not
anticipated to be influenced by or to affect the pharma-
cokinetics of the 3D regimen. Indeed, no significant phar-
macokinetic interaction was observed in a DDI study
wherein warfarin was given concomitantly with the 3D
regimen (Fig. 1) [25]. Of note, although dose adjustment is
not indicated for the vitamin K antagonists warfarin and
acenocoumerol when given with the 3D regimen,
appropriate international normalized ratio monitoring is
advisable according to routine clinical practice.
No dose adjustment is necessary for phenprocoumon, a
vitamin K antagonist, although careful international nor-
malized ratio monitoring is recommended when given with
the 3D regimen based on its pharmacokinetic profile and
drug interaction data with other relevant medications [89].
It is suspected that the impact of CYP3A4, which is
involved in the metabolism of phenprocoumon, is miti-
gated by the role of CYP2C9 and the notable portion of the
administered drug that is excreted unchanged [90].
CYP3A4 and/or P-gp inhibition with the 3D regimen
has implications for the use of apixaban, rivaroxaban, and
dabigatran. Apixaban labeling recommends that the dose
be reduced to 2.5 mg twice daily when given in combi-
nation with strong inhibitors of CYP3A4 and P-gp, such as
ritonavir [91]. Rivaroxaban is contraindicated for use with
strong dual inhibitors of CYP3A and P-gp such as keto-
conazole and ritonavir [92] and, hence, should not be used
with the 3D regimen. As a substrate of P-gp, dabigatran
exposure is influenced by P-gp inhibition [93]. Although
levels of the P-gp substrate digoxin were not significantly
affected by the 3D regimen in a DDI study [25], exposures
for dabigatran may increase as a result of intestinal P-gp
inhibition by paritaprevir and ritonavir. Dabigatran should
be used with caution with 3D therapy and appropriate
international normalized ratio monitoring is advisable
according to routine clinical practice.
An interaction with the purinergic receptor P2Y, G
protein-coupled, 12 (P2Y12) antagonist clopidogrel is
possible based on the involvement of CYP2C19 and
CYP3A4/5 in its metabolism and bioactivation [94, 95].
While the requirement for dose adjustment of clopidogrel
in patients who initiate 3D therapy can be based on clinical
judgment, therapeutic drug level monitoring for clopido-
grel does not appear to be routine clinical practice. Hence,
if clopidogrel cannot be avoided or substituted, it should be
used with caution, or consideration can be given to use of
an alternative DAA regimen that does not have interaction
potential with this medication.
Conversion of prasugrel, a newer generation P2Y12
receptor antagonist, to its active metabolite is primarily
dependent on CYP3A4 and CYP2B6, with some contri-
bution by CYP2C9 and CYP2C19 [96]. Treatment with
100 mg ritonavir has been shown to decrease the Cmax and
AUC of the active metabolite of prasugrel by 45 and 38 %,
respectively [97]. This effect was attributed to inhibition of
CYP3A4 by ritonavir. Nevertheless, concomitant admin-
istration of ketoconazole, a potent inhibitor of CYP3A4
and CYP3A5, with prasugrel did not impact inhibition of
platelet aggregation by prasugrel despite a 34–46 %
decrease in the Cmax of the active metabolite of prasugrel
[96]. A similar magnitude of interaction to that observed
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with ritonavir or ketoconazole is expected with the 3D
regimen. Dose alteration is, therefore, not needed for pra-
sugrel when initially administered with the 3D regimen;
however, monitoring is recommended and dose adjustment
should be enacted, if clinically indicated.
3.6 Antihypertensive Agents
Beta-blockers can generally be divided into two categories:
those that do not undergo extensive metabolism by multi-
ple enzymes in the liver (e.g., atenolol, bisoprolol, nadolol,
and sotalol) [98–101] and those with a metabolism that
depends primarily on CYP2D6 (betaxolol, carteolol,
metoprolol, nebivolol, propranolol, and timolol) [102–
107]. An exception to this classification is acebutolol,
which undergoes a high degree of first-pass metabolism in
the liver [108], but which has not been found to be a
substrate of CYP3A4, CYP2D6, CYP2C9, CYP1A2, or
CYP2C19 [109]. In all cases, no interaction between
members of the beta-blocker class and the 3D regimen is
expected.
The metabolic processes and pathways involved in the
disposition of angiotensin-converting enzyme inhibitors
(e.g., hydrolysis, glucuronidation, dimerization, cycliza-
tion, and renal elimination) [110–117] are generally not
anticipated to be affected by concomitant administration of
the 3D regimen. Thus, no dose adjustment is indicated for
captopril, fosinopril, lisinopril, perindopril, quinopril,
ramipril, or zofenopril. One exception to this overarching
guidance is enalapril, which is an OATP1B1 substrate
[118]. The 3D regimen has been shown to increase expo-
sures of OATP1B1/B3 substrates [25] and, hence, a
reduction in enalapril dose is advised for patients who are
being treated with the 3D regimen.
The importance of CYP3A to the metabolism of cal-
cium channel blockers and the inhibitory effects of certain
calcium channel blockers on CYP3A are potential sources
of interaction when combined with the 3D regimen [119–
126]. With this in mind, a DDI study was conducted
between the 3D regimen and the calcium channel blocker,
amlodipine. Concomitant administration of the 3D regi-
men increased amlodipine exposure by up to 157 % [25].
Consequently, a 50 % dose reduction is recommended for
amlodipine when given with the 3D regimen. Based on
the prescribing information regarding use with CYP3A4
inhibitors and the potential for interaction [120, 122–125],
the lowest possible starting dose should be used for dil-
tiazem, nicardipine, nifedipine, nitrendipine, and vera-
pamil when prescribed to patients receiving the 3D
regimen. Both felodipine and nisoldipine have demon-
strated a substantial interaction with CYP3A inhibitors
(e.g., grapefruit juice, ketoconazole), which increases drug
exposure by several fold [121, 126]. Therefore, neither
felodipine nor nisoldipine should be given in conjunction
with the 3D regimen.
Involvement of OATP transporters has been implicated
in the disposition of many angiotensin II receptor blocker
family members [127–130]. Because of the influence of the
3D regimen on OATP1B1/B3 substrates (Fig. 1) [25], dose
reduction is suggested for OATP-associated angiotensin II
receptor blockers, including candesartan, eprosartan, irbe-
sartan, losartan, olmesartan, telmisartan, and valsartan.
Azilsartan disposition, in contrast, does not appear to
involve OATP transporters and no other overlapping
metabolic pathways with the 3D regimen have been iden-
tified [131]. Dose adjustment is, therefore, not necessary
when azilsartan is administered with the 3D regimen.
No overlapping metabolic or transporter pathways have
been identified between the aldosterone antagonist
spironolactone and the 3D regimen [132, 133]. Hence, no
dose adjustment would be required.
3.7 Antiarrhythmic Agents
The pharmacokinetics of digoxin were only minimally
affected when given as a single dose (0.5 mg) to patients
who had achieved steady state on the 3D regimen, sug-
gesting that no dose adjustment is necessary for this
combination therapy [25]. Based on the known metabolic
pathways, drug–drug interaction is also not expected for
other antiarrhythmic drugs whose metabolism involves
CYP2D6 (flecainide) [134] or CYP2D6/CYP1A2 (mex-
iletine) [135]. However, these antiarrhythmic agents have a
narrow therapeutic index; therefore, caution and thera-
peutic drug monitoring is suggested as part of routine
clinical practice when these drugs are administered with
the 3D regimen.
The involvement of CYP3A4 in the metabolism of
amiodarone [136], disopyramide [137], dronedarone [138,
139], propafenone [140], and quinidine [141] signals a
possible increase in exposure when given with the 3D
regimen owing to inhibitory effects on CYP3A4. If these
agents cannot be avoided or substituted, they should be
used cautiously, with careful monitoring and consideration
for dose reduction, or use of an alternative DAA regimen
that does not have interaction potential with these
medications.
3.8 Antidiabetic Agents
Drug interactions are unlikely with the 3D regimen and
most antidiabetic agents. Processes involved in the dispo-
sition of most approved antidiabetic agents, including uri-
nary excretion (acarbose, metformin, sitagliptin) [142–
144], hydrolysis (vildagliptin) [145], and metabolism via
CYP1A1 (pioglitazone) [146], CYP2C8 (pioglitazone,
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rosiglitazone, sitagliptin) [144, 146, 147], and/or CYP2C9
(glimepiride, glipizide, rosiglitazone, tolbutamide) [147–
152], are unlikely to affect the pharmacokinetics of the 3D
regimen, nor is the 3D regimen likely to influence expo-
sures to these drugs. In a DDI study of the 3D regimen with
metformin, changes in metformin drug exposure during
concomitant administration were not clinically significant
(B23 % decrease) [26].
The magnitude of CYP3A4 involvement in the meta-
bolism of other antidiabetic agents influences the degree of
interaction potential with the 3D regimen. Labeled guid-
ance suggests a dose limitation to 2.5 mg once daily for
saxagliptin, a substrate of CYP3A4, when given in con-
junction with a strong CYP3A4 inhibitor, such as the 3D
regimen [153]. Dose reduction is recommended for
repaglinide, a substrate of CYP2C8, CYP3A4, and
OATP1B1 [154], when used with the 3D regimen. Mech-
anistically, interaction is possible through both inhibition
of CYP3A4 and OATP1B1 by the 3D regimen [24]; DDI
studies of the 3D regimen with OATP1B1/B3 substrates
[25] and repaglinide with OATP1B1 inhibitors support a
potential interaction [155, 156]. Inhibition of OATP by the
3D regimen may also increase exposure to glibenclamide
(glyburide); hence, dose reduction is recommended for
glibenclamide when administered with the 3D regimen [25,
157]. In contrast, because CYP3A4 only plays a minor role
in the metabolism of sitagliptin and the majority of the
drug (79 %) is excreted unchanged in urine [144], the
effect of 3D-mediated CYP3A4 inhibition on sitagliptin
pharmacokinetics is expected to be minimal in patients
with normal renal function. However, in patients with
severe renal impairment or end-stage renal disease, sita-
gliptin exposure may increase when co-administered with
the 3D regimen.
3.9 Lipid-Modifying Therapies
As described above, studies of the 3D regimen with
pravastatin or rosuvastatin revealed increases in exposure
for both of these drugs [25]. To accommodate these
changes, it is recommended that pravastatin dose be
reduced by half and that the rosuvastatin dose is limited to
5 or 10 mg when prescribed to patients receiving the 3D
regimen. As substrates of OATP1B1 and/or OATP1B3
[127], the pharmacokinetics of atorvastatin, cerivastatin,
ezetimibe, fluvastatin, and pitavastatin may also be influ-
enced by the 3D regimen. Although CYP3A4 does play a
role in the metabolism of the aforementioned statins [127,
158], atorvastatin is the only one for which it is the dom-
inant CYP species [159]. Atorvastatin is, hence, not rec-
ommended with the 3D regimen. If a statin is required,
clinicians should use the lowest available dose of cerivas-
tatin, ezetimibe, fluvastatin, and pitavastatin, or switch to a
reduced recommended doses of pravastatin/rosuvastatin
when given concomitantly with the 3D regimen.
No overlap in metabolic or transporter pathways with
the 3D regimen was identified for niacin, omega-3 fatty
acids, and mipomersen; these agents can be administered
with the 3D regimen without dose adjustment [160–162].
Fenofibric acid, the pharmacologically active moiety of
fenofibrate and choline fenofibrate, undergoes glu-
curonidation by several UGT species, including UGT1A1,
UGT1A3, UGT1A9, and UGT2B7 [163]. The contribution
of UGT1A1 to this process is comparatively modest.
Therefore, dose adjustment is not indicated, although
monitoring is suggested for fenofibric acid.
As anion exchange resins, the bile acid sequestrants
colestipol and colesevelam may bind to molecules other
than their intended targets [164, 165]. This may lead to
delayed or incomplete absorption of concomitantly
administered oral medications. Consistent with prescribing
guidance for bile acid sequestrants and the absorption
window of the 3D regimen, it is recommended that the
administration of bile acid sequestrants should be separated
from the 3D regimen administration by at least 4 h.
Several lipid-modifying agents should not be given in
conjunction with the 3D regimen, including gemfibrozil,
lovastatin, and simvastatin. Gemfibrozil was shown to
mediate a substantial increase (approximately ten-fold) in
dasabuvir exposure when administered with paritaprevir/r
and dasabuvir (Fig. 1) [25]. Recommendations for using
lovastatin and simvastatin are based on the labeled con-
traindication for combination with CYP3A inhibitors
because of an increased risk for myopathy, including
rhabdomyolysis [58].
3.10 a1-Adrenergic Blockers
The use of a1-adrenergic blockers have several restrictions
based on their CYP3A4-dependent metabolism [166–168].
Neither tamsulosin or alfuzosin should be given with the
3D regimen because of restrictions on their use with
CYP3A inhibitors in their respective labels [166, 168].
However, doxazosin can be used with caution and dose
reduction [167].
3.11 b-Adrenergic Agonists
There are no overlapping metabolic/transporter pathways
between albuterol (salbutamol) and 3D regimen compo-
nents [169]. Hence, a drug interaction is not expected
between albuterol and the 3D regimen and no dose
adjustment is necessary when administered together.
The metabolism of formoterol involves an array of
enzymes, some of which (UGT1A1, CYP2C19) are known
to be affected by the 3D regimen [170]. Given the potential
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for altering drug pharmacokinetics, formoterol should be
used with caution and dose reduction should be imple-
mented if clinically indicated. However, concomitant use
of salmeterol, a substrate of CYP3A4, is not recommended
with the 3D regimen because of the potential for QTc
prolongation, palpitation, and sinus tachycardia [171].
3.12 Hypnotic/Sedative Agents
Recommendations for co-administration of hypnotic/
sedative agents differ by individual drugs. CYP3A4 plays
a dominant role in the metabolism of many hypnotic/
sedative agents, including that of alprazolam, clonazepam,
eszopiclone, estazolam, flunitrazepam, prazepam, quaze-
pam, and zaleplon and zopiclone [172–180]. Because of
the inhibitory effect of the 3D regimen on this enzyme,
dose reduction is generally recommended when these
agents are administered to patients receiving 3D treat-
ment. The recommended dose adjustment is supported by
a DDI study with alprazolam in which the drug’s AUC
increased by 34 % when administered with the 3D regi-
men [25].
Notable exceptions to the dose reduction guidance
include diazepam, zolpidem, triazolam, and midazolam.
Changes in exposures for diazepam, a substrate of both
CYP3A4 and CYP2C19 [181], were modest (22 %
decrease in AUC and 18 % increase in Cmax) when co-
administered with the 3D regimen in a DDI study [26].
However, the Cmax of nordiazepam, the major metabolite
of diazepam, increased by 10 % and the AUC for a dosing
interval and AUC from 0 to infinity (AUCinf) decreased by
3 and 44 %, respectively. Because of its long half-life
(137 h), AUCinf was not reliably estimated when diazepam
was dosed alone. Given these results, diazepam dose can be
increased, if clinically indicated, although pre-emptive
dose adjustments are not required. When given concomi-
tantly with the 3D regimen in a DDI study, zolpidem
pharmacokinetics were not appreciably affected; therefore,
dose reduction is not indicated [25]. Triazolam and oral
midazolam, in contrast, are contraindicated for use with
medications that impair CYP3A function [58, 182], and
should, therefore, not be given with the 3D regimen.
Although the effect of the 3D regimen on midazolam
exposure is expected to be significantly less with parenteral
administration, close monitoring for respiratory depression
and/or prolonged sedation are recommended and dose
adjustment may be considered [58].
Another potential influence on DDI risk with hypnotics/
sedatives is glucuronidation involving different members
of the UGT family. Delayed plasma clearance of lor-
azepam resulting from inhibition of glucuronidation has
been observed in clinical studies [183, 184]. Given the
influence of the 3D regimen on UGT1A1 substrates
(Fig. 1) [25], lorazepam dose reduction is suggested. Dose
reduction, however, is not required for oxazepam and
temazepam owing to the minimal involvement of UGT1A1
in their glucuronidation [185]. In general, clinical moni-
toring should be considered for all hypnotic/sedative
agents, irrespective of the dose adjustment
recommendation.
3.13 Antiepileptic Agents
Methods of disposition for many antiepileptic drugs,
including renal elimination (felbamate, gabapentin, topi-
ramate, vigabatrin) [186–189] and hydrolysis (levetirac-
etam) [190], are generally not anticipated to be influenced
by the 3D regimen. Dose alteration is also not anticipated
for sodium valproate, whose metabolism involves multiple
UGT and CYP species [191]; however, therapeutic drug
monitoring is recommended when initiating co-
administration.
Exposure to drugs that are metabolized by CYP3A4,
including tiagabine [192] and zonisamide [193], may
increase with concomitant 3D therapy. These drugs should
be used with caution and dose reduction should be con-
sidered. Dose alteration and patient monitoring may also be
required for lamotrigine owing to UGT1A1 induction by
ritonavir [28].
Carbamazepine, phenobarbital, and phenytoin are
inducers of CYP3A4 [194]. In a DDI study with the 3D
regimen, carbamazepine appreciably decreased DAA
exposure (Fig. 1) [25]. Because of the potential for loss of
therapeutic efficacy, carbamazepine, phenobarbital, and
phenytoin are contraindicated for use with the 3D regimen.
3.14 Steroids
Co-administration of ritonavir with corticosteroids that are
metabolized by CYP3A4 (e.g., budesonide, dexametha-
sone, fluticasone, methylprednisolone, mometasone,
prednisone, and triamcinolone) increases steroid concen-
trations and can lead to iatrogenic Cushing syndrome and
adrenal suppression [58, 195–200]. Caution should be
exercised and lowest doses should be used when consid-
ering use of these agents with the 3D regimen. In par-
ticular, budesonide and fluticasone, especially if
prescribed for long-term use, should only be initiated if
the potential benefit of treatment outweighs the risk of
systemic corticosteroid effects.
Beclomethasone dipropionate appears to be less prone to
interactions with ritonavir. Direct combination of ritonavir
with beclomethasone increased exposures of its metabolite,
beclomethasone-17-monopropionate (17-BMP), but not to
a level that was considered to be clinically significant
[201]. Interestingly, 17-BMP exposure was not appreciably
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increased when darunavir and ritonavir were both admin-
istered with beclomethasone. Beclomethasone is an
acceptable alternative inhaled/intranasal corticosteroid
option for patients receiving the 3D regimen. The phar-
macokinetic characteristics of ciclesonide generate lower
systemic exposure than other inhaled/intranasal corticos-
teroids [202]. Ciclesonide may be given without dose
adjustment to patients treated with the 3D regimen, with
the caveat that monitoring for steroid-related side effects
should be ongoing.
The use of topical corticosteroid creams or lotions with
the 3D regimen is permissible with attention to factors that
can increase systemic absorption such as use over large
body surface areas or prolonged use, as described in pre-
scribing information.
3.15 Antibiotics
Beta-lactams and fluroquinolones can be given with the
3D regimen without dose adjustment because they are
predominantly excreted unchanged in urine or bile [203–
207] and there are no apparent overlapping
metabolic/transporter pathways between these antibiotics
and the 3D regimen [203, 205, 206]. The possible
involvement of P-gp in azithromycin disposition [208] is
not believed to have an appreciable impact on drug
pharmacokinetics, given the lack of significant interaction
detected with the 3D regimen and digoxin, a model P-gp
substrate (Fig. 1) [25]. Clarithromycin is a strong inhibitor
of CYP3A4 [207], through which an interaction with the
3D regimen is possible. Nonetheless, a pharmacokinetic
evaluation of concomitant ritonavir and clarithromycin
determined that no dose adjustment was required for
either agent when co-administered to patients with normal
renal function [209]. Clarithromycin dose reduction is,
however, recommended for patients with moderate or
severe renal impairment [207].
Clinically significant interactions were not observed
between sulfamethoxazole/trimethoprim and the 3D regi-
men in a DDI study. The moderate increase (33 %) in
dasabuvir exposure is attributable to the weak CYP2C8
inhibitory effects of trimethoprim [26]. Exposures to
sulfamethoxazole and trimethoprim modestly increased
(\25 %). The magnitude of these changes does not indi-
cate that dose adjustment is needed for either the 3D
regimen or sulfamethoxazole/trimethoprim during co-
administration.
Metabolic pathways for fusidic acid are not currently
known, but interaction with drugs metabolized by CYP3A4
is suspected [210]. It is recommended that fusidic acid not
be given to patients who are receiving a drug or drugs that
are metabolized by CYP3A4. As such, fusidic acid is
contraindicated for use with the 3D regimen.
3.16 Antifungals
A potential for interaction with the 3D regimen exists for
several antifungal agents, including ketoconazole, itra-
conazole, posaconazole, and voriconazole, by virtue of
their metabolism by or effects on CYP3A4. In a DDI study,
the AUC of ketoconazole (a CYP3A4/P-gp inhibitor and
CYP3A4 substrate) increased by 117 % when a single dose
of the 3D regimen was added to steady-state ketoconazole
400 mg once daily [25]. Although ombitasvir, paritaprevir,
ritonavir, and dasabuvir exposures also increased, none of
the changes were considered clinically significant. Similar
increases are possible with itraconazole, another CYP3A4/
P-gp inhibitor and CYP3A4 substrate [211]. As a strong
inhibitor of CYP3A4, caution is advised when posacona-
zole is administered with drugs metabolized by CYP3A4,
including ritonavir [212]. Alterations in voriconazole
exposure are also possible owing to its metabolism by
CYP2C19 and CYP3A4 [213]. Unlike the azoles,
echinocandins such as capsofungin, micafungin, and
anidulafungin do not have primary interactions with CYP
enzymes or P-gp [214–216]; therefore, a drug interaction is
not expected between these drugs and the 3D regimen.
In summary, in patients being treated with the 3D reg-
imen, daily doses of greater than 200 mg are not recom-
mended for either ketoconazole or itraconazole, and use of
a lower posaconazole dose is advised. Co-administration of
voriconazole with the 3D regimen should be avoided
unless an assessment of the benefit-to-risk balance justifies
its use. Echinocandins can be administered with the 3D
regimen without any dose modification.
3.17 Oral Contraceptives
Interactions with the 3D regimen have been evaluated for
progestin-only contraceptives and combined oral contra-
ceptives. Minimal effects on drug exposures were observed
when norethindrone 0.35 mg (a progestin-only contracep-
tive) was administered with the 3D regimen. However, use
of 3D therapy with norgestimate (250 lg) plus ethinyl
estradiol (35 lg) significantly increased the levels of
norgestimate metabolites and appreciably decreased pari-
taprevir, ritonavir, and dasabuvir exposures. Moreover,
asymptomatic alanine transaminase elevations were
observed when the 3D regimen was combined with
norgestimate (250 lg) plus ethinyl estradiol (35 lg) or
norethindrone (0.40 mg) plus ethinyl estradiol (35 lg) [12,
25]. Given the potential for alanine transaminase elevations
in women who use ethinyl estradiol-containing medica-
tions such as combined oral contraceptives, contraceptive
patches, or contraceptive vaginal rings, these medications
must be discontinued at least 2 weeks prior to starting
therapy with the 3D regimen. Alternative methods of
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contraception (e.g., progestin-only contraception or non-
hormonal methods) are recommended during 3D therapy.
Ethinyl estradiol-containing medications can be restarted
approximately 2 weeks after completion of 3D treatment
[12, 25]. If ethinyl estradiol-containing oral contraceptives
cannot be avoided or substituted, consideration can be
given to use of an alternative DAA regimen that does not
have interaction potential with these medications.
3.18 Phosphodiesterase Type 5 Inhibitors
The predominant route of metabolism for phosphodi-
esterase type 5 (PDE5) inhibitors is through CYP3A family
members [217–220]. As such, PDE5 inhibitor clearance is
expected to be reduced in the presence of CYP3A inhibi-
tors, including the 3D regimen. Guidance for use of PDE5
inhibitors with CYP3A inhibitors is dependent on the
therapeutic indication. In the absence of data for the 3D
regimen, limitations and contraindications suggested for
low-dose ritonavir can be applied.
PDE5 inhibitors are used both in the treatment of
erectile dysfunction and pulmonary arterial hypertension,
at different doses. For the treatment of erectile dysfunction
in patients receiving low-dose ritonavir, doses of sildenafil,
tadalafil, and vardenafil should be limited to 25 mg every
48 h, 10 mg every 72 h, or 2.5 mg every 72 h, respectively
[58]. Avanafil should not be prescribed for patients
receiving 3D, as no safe and effective dose has been
determined when used with low-dose ritonavir therapy. In
patients with pulmonary arterial hypertension, combining
sildenafil with low-dose ritonavir is contraindicated
because of a lack of an established safe and effective dose.
For patients with pulmonary arterial hypertension, con-
sideration can be given to use of an alternative DAA reg-
imen that does not have interaction potential with
sildenafil. Tadalafil and vardenafil 20 mg once daily may
be initiated after at least 1 week of low-dose ritonavir
treatment. The dose may be increased to 40 mg once daily
if tolerated and clinically indicated. Increased monitoring
for AEs is recommended during concomitant PDE5 inhi-
bitor/3D therapy.
3.19 Thyroid Replacement Therapy
Many of the drugs that are commonly used by patients with
HCV are covered within the classes discussed above.
Based on a recent evaluation of prescription patterns in
patients with chronic HCV [21], one additional medication
that is often prescribed to patients with HCV is worthy of
note. Levothyroxine sodium is a frequent concomitant
medication among patients with chronic HCV owing to the
elevated prevalence of hypothyroidism in this population
[221]. Levothyroxine is a sensitive substrate that is thought
to be metabolized by UGT1A1 [222] without the con-
founding influence of other UGTs or CYPs. Increases in
thyroxine concentration have been observed with UGT1A1
inhibitors such as indinavir [223]. Based on results of the
3D/UGT1A1 substrate DDI study (Fig. 1), concomitant use
of levothyroxine with the 3D regimen may increase con-
centrations of levothyroxine. Hence, thyroid-stimulating
hormone levels should be carefully monitored in patients
receiving levothyroxine and 3D and dose adjustment
implemented based on the clinical response.
Two classes of agents that are absent from this discus-
sion are medications used in the treatment of HIV and
immunosuppressants used to prevent transplant rejection
(e.g., cyclosporine and tacrolimus). The results of ongoing
and completed studies [224] with these agents will be
presented in a separate review.
4 Clinical Experience with the 3D Regimen
The 3D regimen has been evaluated with or without rib-
avirin in six phase III clinical trials that enrolled more than
2300 patients infected with genotype-1 HCV [5, 8–11].
Patients were allowed to continue most of their co-medi-
cations while receiving study drug treatment, although dose
adjustment was permissible and recommended. More than
1200 co-medications belonging to 15 drug classes and 19
enzyme/transporter inhibitor/inducer categories were given
concomitantly with the 3D regimen in these studies [225–
227]. Percentage-of-use metrics based on drug class are
listed in Table 2. Polypharmacy was commonplace, with
approximately 1500 patients (65 %) receiving two or more
concomitant medications from multiple drug classes/cate-
gories [227]. Patient monitoring and dose adjustment, as
necessary, were sufficient to manage any potential DDIs.
The 3D regimen with or without ribavirin was well toler-
ated in treatment-naı¨ve and treatment-experienced HCV-
infected patients with and without cirrhosis [12]; the rate of
study drug discontinuation due to AEs was low (\1 %) and
few serious AEs were reported.
5 Conclusions
Our analysis suggests that the 3D regimen is compatible
with many of the drugs that are commonly used by patients
with HCV infection. Where an interaction is possible, risk
can be mitigated by careful attention to concomitant
medications, adjusting drug dosage as needed, and moni-
toring patient response and/or clinical parameters. As HCV
3D therapy is indicated for only 12–24 weeks, clinicians
may choose to either suspend existing or new interacting
medications or clinically manage the potential DDIs over
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the fixed, short-term, 3D regimen treatment duration. By
using these strategies with the drug-specific guidance
provided herein, the likelihood for adverse drug reactions
can be lessened, thereby maximizing the opportunity for
successful treatment of HCV infection. While these rec-
ommendations provide general guidelines based on known
mechanism of disposition for the 3D regimen and various
interaction medications, clinical judgment based on patient
response should prevail during co-administration.
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